Together, our prior work suggests that SBRT+P is safe and feasible, and that factors beyond tumor size or complete tumor irradiation, such as RS, expression of IFN-related pathways, and the presence of certain circulating cytokines, may predict outcomes. The gene discussed is IFNA1; the disease is neoplasm.